GeneDx Investors Face Potential Losses Following Failed Acquisition

The complaint alleges that GeneDx executives consistently overstated the potential of Fabric Genomics to generate recurring software-based revenue. While GeneDx marketed the acquisition as a strategy to expand its addressable market and improve operational efficiency, plaintiffs contend the company ignored significant underlying issues with Fabric's business model. These alleged misrepresentations reached a breaking point on May 4, 2026, when GeneDx reported disappointing first-quarter results and a $31.2 million impairment loss tied to the Fabric acquisition.

Following the announcement, GeneDx slashed its full-year revenue guidance to a range of $475 million to $490 million, down from previous projections of up to $550 million. The market reaction was immediate and severe, with the company's stock price plummeting by $33.42—a 49.2% drop in a single session. Robbins LLP is now seeking investors who suffered financial harm during the class period to serve as lead plaintiffs. Interested parties must file relevant documentation with the court by August 3, 2026.